Pancreatic Cancer: Multicenter Prospective Data Collection and Analysis by the Hungarian Pancreatic Study Group.
OBJECTIVE
Pancreatic cancer is a devastating disease with poor prognosis. There is very limited information available regarding the epidemiology and treatment strategies of pancreatic cancer in Central Europe. The purpose of the study was to prospectively collect and analyze data of pancreatic cancer in the Hungarian population.


METHODS
The Hungarian Pancreatic Study Group (HPSG) organized prospective, uniform data collection. Altogether 354 patients were enrolled from 14 Hungarian centers.


RESULTS
Chronic pancreatitis was present in 3.7% of the cases, while 33.7% of the patients had diabetes. Family history for pancreatic cancer was positive in 4.8%. The most frequent presenting symptoms included pain (63.8%), weight loss (63%) and jaundice (52.5%). The reported frequency of smoking and alcohol consumption was lower than expected (28.5% and 27.4%, respectively). The majority of patients (75.6%) were diagnosed with advanced disease. Most patients (83.6%) had a primary tumor located in the pancreatic head. The histological diagnosis was ductal adenocarcinoma in 90.7% of the cases, while neuroendocrine tumor was present in 5.3%. Biliary stent implantation was performed in 166 patients, 59.2% of them received metal stents. Primary tumor resection was performed in 60 (16.9%) patients. Enteral or biliary bypass was done in 35 and 49 patients, respectively. In a multivariate Cox-regression model, smoking status and presence of gemcitabine-based chemotherapy were identified as independent predictors for overall survival.


CONCLUSIONS
We report the first data from a large cohort of Hungarian pancreatic cancer patients. We identified smoking status and chemotherapy as independent predictors in this cohort.
Dept. Oncology, St. Istvan and St. Laszlo Hospital and Out-Patient Department, Budapest, Hungary.
Gábor
G
Lakatos
1st Dept. Medicine, University of Szeged, Hungary.
Anita
A
Balázs
1st Dept. Medicine, University of Szeged, Hungary.
Balázs
B
Kui
1st Dept. Medicine, University of Pécs, Hungary.
Szilárd
S
Gódi
1st Dept. Surgery, Semmelweis University, Budapest, Hungary.
Ákos
Á
Szücs
1st Dept. Medicine, University of Szeged, Hungary.
Andrea
A
Szentesi
Institute of Surgery, Clinical Center, University of Debrecen, Hungary.
Zsolt
Z
Szentkereszty
Dept. Interventional Gastroenterology, National Institute of Oncology, Budapest, Hungary.
Richárd
R
Szmola
Dept. Surgery, University of Pécs, Hungary.
Dezső
D
Kelemen
Dept. Surgery, University of Pécs, Hungary.
Róbert
R
Papp
1st Dept. Medicine, University of Pécs, Hungary.
Áron
Á
Vincze
1st Dept. Medicine, University of Pécs, Hungary.
József
J
Czimmer
1st Dept. Medicine, University of Pécs, Hungary.
Gabriella
G
Pár
1st Dept. Medicine, University of Pécs, Hungary.
Judit
J
Bajor
1st Dept. Medicine, University of Pécs, Hungary.
Imre
I
Szabó
1st Dept. Medicine, Szent György University Teaching Hospital of County Fejér, Székesfehérvár, Hungary.
Ferenc
F
Izbéki
1st Dept. Medicine, Szent György University Teaching Hospital of County Fejér, Székesfehérvár, Hungary.
Adrienn
A
Halász
Dept. Surgery, University of Szeged, Hungary.
László
L
Leindler
Dept. Surgery, University of Szeged, Hungary.
Gyula
G
Farkas
1st Dept. Medicine, University of Szeged, Hungary.
Tamás
T
Takács
1st Dept. Medicine, University of Szeged, Hungary.
László
L
Czakó
1st Dept. Medicine, University of Szeged, Hungary.
Zoltán
Z
Szepes
1st Dept. Medicine, University of Szeged, Hungarian Academy of Sciences, University of Szeged, Momentum Gastroenterology Multidisciplinary Research Group, Institute for Translational Medicine and 1st Department of Medicine, University of Pécs, Hungary. hegyi2009@gmail.com.
Péter
P
Hegyi
Dept. Oncotherapy, University of Szeged,Szeged, Hungary.
Zsuzsanna
Z
Kahán
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000428:Alcohol Drinking / Q000009:adverse effects / Q000453:epidemiology; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use; D021441:Carcinoma, Pancreatic Ductal / Q000209:etiology / Q000401:mortality / Q000473:pathology / Q000628:therapy; D002760:Cholangiopancreatography, Endoscopic Retrograde / Q000295:instrumentation; D003841:Deoxycytidine / Q000031:analogs & derivatives / Q000627:therapeutic use; D003920:Diabetes Mellitus / Q000453:epidemiology; D005260:Female; D006801:Humans; D006814:Hungary / Q000453:epidemiology; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009367:Neoplasm Staging; D018358:Neuroendocrine Tumors / Q000209:etiology / Q000401:mortality / Q000473:pathology / Q000628:therapy; D010166:Palliative Care; D010180:Pancreatectomy; D010190:Pancreatic Neoplasms / Q000209:etiology / Q000401:mortality / Q000473:pathology / Q000628:therapy; D050500:Pancreatitis, Chronic / Q000453:epidemiology; D011379:Prognosis; D016016:Proportional Hazards Models; D011446:Prospective Studies; D012042:Registries; D012307:Risk Factors; D012907:Smoking / Q000009:adverse effects / Q000453:epidemiology; D015607:Stents; D055815:Young Adult; D000093542:Gemcitabine
D000964:Antimetabolites, Antineoplastic; D003841:Deoxycytidine; D000093542:Gemcitabine